[1]
|
Cecilio, A.P., Takakura, E.T., Jumes, J.J., Dos Santos, J.W., Herrera, A.C., Victorino, V.J. and Panis, C. (2015) Breast Cancer in Brazil: Epidemiology and Treatment Challenges. Breast Cancer, 7, 43-49. https://doi.org/10.2147/BCTT.S50361
|
[2]
|
Ciriello, G., Sinha, R., Hoadley, K.A., Jacobsen, A.S., Reva, B., Perou, C.M., Sander, C. and Schultz, N. (2013) The Molecular Diversity of Luminal A Breast Tumors. Breast Cancer Research and Treatment, 141, 409-420. https://doi.org/10.1007/s10549-013-2699-3
|
[3]
|
Network, C.G.A. (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. https://doi.org/10.1038/nature11412
|
[4]
|
Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.J. and members, P. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24, 2206-2223. https://doi.org/10.1093/annonc/mdt303
|
[5]
|
Ward, E.M., De-Santis, C.E., Lin, C.C., Kramer, J.L., Jemal, A., Kohler, B., Brawley, O.W. and Gansler, T. (2015) Cancer Statistics: Breast Cancer in Situ. CA: A Cancer Journal for Clinicians, 65, 481-495. https://doi.org/10.3322/caac.21321
|
[6]
|
Esserman, L. and Yau, C. (2015) Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncology, 1, 881-883. https://doi.org/10.1001/jamaoncol.2015.2607
|
[7]
|
Khan, S., Epstein, M., Lagios, M.D. and Silverstein, M.J. (2017) Are We Overtreating Ductal Carcinoma In Situ (DCIS)? Annals of Surgical Oncology, 24, 59-63. https://doi.org/10.1245/s10434-016-5501-z
|
[8]
|
Gorringe, K.L. and Fox, S.B. (2017) Ductal Carcinoma. Frontiers in Oncology, 7, 248. https://doi.org/10.3389/fonc.2017.00248
|
[9]
|
Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred, N.J., Forbes, J.F., Bishop, H., Fentiman, I.S. and George, W.D. (2011) Effect of Tamoxifen and Radiotherapy in Women with Locally Excised Ductal Carcinoma In Situ: Long-Term Results from the UK/ANZ DCIS Trial. The Lancet Oncology, 12, 21-29. https://doi.org/10.1016/S1470-2045(10)70266-7
|
[10]
|
Fong, J., Kurniawan, E.D., Rose, A.K., Mou, A., Collins, J.P., Miller, J.A. and Mann, G.B. (2011) Outcomes of Screening-Detected Ductal Carcinoma In Situ Treated with Wide Excision Alone. Annals of Surgical Oncology, 18, 3778-3784. https://doi.org/10.1245/s10434-011-1748-6
|
[11]
|
Benson, J.R. and Wishart, G.C. (2013) Predictors of Recurrence for Ductal Carcinoma In Situ after Breast-Conserving Surgery. The Lancet Oncology, 14, e348-e357. https://doi.org/10.1016/S1470-2045(13)70135-9
|
[12]
|
Kerlikowske, K., Molinaro, A.M., Gauthier, M.L., Berman, H.K., Waldman, F., Bennington, J., Sanchez, H., Jimenez, C., Stewart, K., Chew, K., Ljung, B.M. and Tlsty, T.D. (2010) Biomarker Expression and Risk of Subsequent Tumors after Initial Ductal Carcinoma In Situ Diagnosis. Journal of the National Cancer Institute, 102, 627-637. https://doi.org/10.1093/jnci/djq101
|
[13]
|
Hwang, E.S., McLennan, J.L., Moore, D.H., Crawford, B.B., Esserman, L.J. and Ziegler, J.L. (2007) Ductal Carcinoma In Situ in BRCA Mutation Carriers. Journal of Clinical Oncology, 25, 642-647. https://doi.org/10.1200/JCO.2005.04.0345
|
[14]
|
Narod, S.A., Iqbal, J., Giannakeas, V., Sopik, V. and Sun, P. (2015) Breast Cancer Mortality after a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 1, 888-896. https://doi.org/10.1001/jamaoncol.2015.2510
|
[15]
|
Ellis, I.O., Coleman, D., Wells, C., Kodikara, S., Paish, E.M., Moss, S., Al-Sam, S., Anderson, N., Bobrow, L., Buley, I., Connolly, C.E., Dallimore, N.S., Hales, S., Hanby, A., Humphreys, S., Knox, F., Lowe, J., Macartney, J., Nash, R., Parham, D., Patnick, J., Pinder, S.E., Quinn, C.M., Robertson, A.J., Shrimankar, J., Walker, R.A. and Winder, R. (2006) Impact of a National External Quality Assessment Scheme for Breast Pathology in the UK. Journal of Clinical Pathology, 59, 138-145. https://doi.org/10.1136/jcp.2004.025551
|
[16]
|
Allred, D.C., Mohsin, S.K. and Fuqua, S.A. (2001) Histological and Biological Evolution of Human Premalignant Breast Disease. Endocrine-Related Cancer, 8, 47-61. https://doi.org/10.1677/erc.0.0080047
|
[17]
|
Yarnold, J. (2009) Early and Locally Advanced Breast Cancer: Diagnosis and Treatment National Institute for Health and Clinical Excellence Guideline 2009. Clinical Oncology, 21, 159-160. https://doi.org/10.1016/j.clon.2008.12.008
|
[18]
|
Tamimi, R.M., Baer, H.J., Marotti, J., Galan, M., Galaburda, L., Fu, Y., Deitz, A.C., Connolly, J.L., Schnitt, S.J., Colditz, G.A. and Collins, L.C. (2008) Comparison of Molecular Phenotypes of Ductal Carcinoma In Situ and Invasive Breast Cancer. Breast Cancer Research, 10, R67. https://doi.org/10.1186/bcr2128
|
[19]
|
Poulakaki, N., Makris, G.M., Battista, M.J., Böhm, D., Petraki, K., Bafaloukos, D., Sergentanis, T.N., Siristatidis, C., Chrelias, C. and Papantoniou, N. (2016) Hormonal Receptor Status, Ki-67 and HER2 Expression: Prognostic Value in the Recurrence of Ductal Carcinoma In Situ of the Breast? Breast, 25, 57-61. https://doi.org/10.1016/j.breast.2015.10.007
|
[20]
|
Hammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., McShane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L. and Wolff, A.C. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 28, 2784-2795. https://doi.org/10.1200/JCO.2009.25.6529
|
[21]
|
Horimoto, Y., Terao, T., Tsutsumi, Y., Tanabe, M., Mogushi, K., Hlaing, M.T., Sasaki, R., Saeki, H., Okazaki, M., Sonoue, H., Arakawa, A. and Saito, M. (2019) Estrogen Receptor-Positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein without Gene Amplification. The American Journal of Surgical Pathology, 43, 1221-1228. https://doi.org/10.1097/PAS.0000000000001300
|
[22]
|
Polónia, A., Oliveira, G. and Schmitt, F. (2017) Characterization of HER2 Gene Amplification Heterogeneity in Invasive and In Situ Breast Cancer Using Bright-Field In Situ Hybridization. Virchows Arch, 471, 589-598. https://doi.org/10.1007/s00428-017-2189-9
|
[23]
|
Bustreo, S., Osella-Abate, S., Cassoni, P., Donadio, M., Airoldi, M., Pedani, F., Papotti, M., Sapino, A. and Castellano, I. (2016) Optimal Ki67 Cut-Off for Luminal Breast Cancer Prognostic Evaluation: A Large Case Series Study with a Long-Term Follow-Up. Breast Cancer Research and Treatment, 157, 363-371. https://doi.org/10.1007/s10549-016-3817-9
|
[24]
|
Murray, C., Flanagan, L., D’Arcy, C., Gullo, G. and Quinn, C.M. (2020) Assessing the Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists Recommendations on Human Epidermal Growth Factor Receptor 2 Testing by Fluorescence In Situ Hybridization in Breast Carcinoma. Virchows Arch, 476, 367-372. https://doi.org/10.1007/s00428-019-02636-3
|
[25]
|
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M.S., Durbecq, V., Sotiriou, C., Larsimont, D., Piccart-Gebhart, M.J. and Paesmans, M. (2007) Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-Analysis of Published Studies Involving 12, 155 Patients. British Journal of Cancer, 96, 1504-1513. https://doi.org/10.1038/sj.bjc.6603756
|
[26]
|
Hoda, S.A., Chiu, A., Prasad, M.L., Giri, D. and Hoda, R.S. (2000) Are Microinvasion and Micrometastasis in Breast Cancer Mountains or Molehills? The American Journal of Surgery, 180, 305-308. https://doi.org/10.1016/S0002-9610(00)00464-5
|
[27]
|
Nekhlyudov, L., Habel, L.A., Achacoso, N., Jung, I., Haque, R., Collins, L.C., Schnitt, S.J., Quesenberry, C.P. and Fletcher, S.W. (2012) Ten-Year Risk of Diagnostic Mammograms and Invasive Breast Procedures after Breast-Conserving Surgery for DCIS. Journal of the National Cancer Institute, 104, 614-621. https://doi.org/10.1093/jnci/djs167
|
[28]
|
Collins, L.C., Tamimi, R.M., Baer, H.J., Connolly, J.L., Colditz, G.A. and Schnitt, S.J. (2005) Outcome of Patients with Ductal Carcinoma In Situ Untreated after Diagnostic Biopsy: Results from the Nurses’ Health Study. Cancer, 103, 1778-1784. https://doi.org/10.1002/cncr.20979
|
[29]
|
Erbas, B., Provenzano, E., Armes, J. and Gertig, D. (2006) The Natural History of Ductal Carcinoma In Situ of the Breast: A Review. Breast Cancer Research and Treatment, 97, 135-144. https://doi.org/10.1007/s10549-005-9101-z
|
[30]
|
Sanders, M.E., Schuyler, P.A., Simpson, J.F., Page, D.L. and Dupont, W.D. (2015) Continued Observation of the Natural History of Low-Grade Ductal Carcinoma In Situ Reaffirms Proclivity for Local Recurrence Even after More than 30 Years of Follow-Up. Modern Pathology, 28, 662-669. https://doi.org/10.1038/modpathol.2014.141
|
[31]
|
Stuart, K.E., Houssami, N., Taylor, R., Hayen, A. and Boyages, J. (2015) Long-Term Outcomes of Ductal Carcinoma In Situ of the Breast: A Systematic Review, Meta-Analysis and Meta-Regression Analysis. BMC Cancer, 15, 890. https://doi.org/10.1186/s12885-015-1904-7
|
[32]
|
Virnig, B.A., Tuttle, T.M., Shamliyan, T. and Kane, R.L. (2010) Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. Journal of the National Cancer Institute, 102, 170-178. https://doi.org/10.1093/jnci/djp482
|
[33]
|
(1997) Consensus Conference on the Classification of Ductal Carcinoma in Situ. Human Pathology, 28, 1221-1225. https://doi.org/10.1016/S0046-8177(97)90193-3
|
[34]
|
Chapman, J.A., Miller, N.A., Lickley, H.L., Qian, J., Christens-Barry, W.A., Fu, Y., Yuan, Y. and Axelrod, D.E. (2007) Ductal Carcinoma In Situ of the Breast (DCIS) with Heterogeneity of Nuclear Grade: Prognostic Effects of Quantitative Nuclear Assessment. BMC Cancer, 7, 174. https://doi.org/10.1186/1471-2407-7-174
|
[35]
|
Elshof, L.E., Schmidt, M.K., Rutgers, E.J.T., van Leeuwen, F.E., Wesseling, J. and Schaapveld, M. (2018) Cause-Specific Mortality in a Population-Based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of Surgery, 267, 952-958. https://doi.org/10.1097/SLA.0000000000002239
|
[36]
|
Worni, M., Akushevich, I., Greenup, R., Sarma, D., Ryser, M.D., Myers, E.R. and Hwang, E.S. (2015) Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal of the National Cancer Institute, 107, djv263. https://doi.org/10.1093/jnci/djv263
|
[37]
|
Quinn, C.M. and Ostrowski, J.L. (1997) Cytological and Architectural Heterogeneity in Ductal Carcinoma In Situ of the Breast. Journal of Clinical Pathology, 50, 596-599. https://doi.org/10.1136/jcp.50.7.596
|
[38]
|
Zhou, W., Jirström, K., Amini, R.M., Fjällskog, M.L., Sollie, T., Lindman, H., Sørlie, T., Blomqvist, C. and Wärnberg, F. (2013) Molecular Subtypes in Ductal Carcinoma In Situ of the Breast and Their Relation to Prognosis: A Population-Based Cohort Study. BMC Cancer, 13, 512. https://doi.org/10.1186/1471-2407-13-512
|
[39]
|
Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P.S., Parker, J.S., Perou, C.M., Ellis, M.J. and Nielsen, T.O. (2009) Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer. Journal of the National Cancer Institute, 101, 736-750. https://doi.org/10.1093/jnci/djp082
|
[40]
|
Lazzeroni, M., Guerrieri-Gonzaga, A., Botteri, E., Leonardi, M.C., Rotmensz, N., Serrano, D., Varricchio, C., Disalvatore, D., Del Castillo, A., Bassi, F., Pagani, G., DeCensi, A., Viale, G., Bonanni, B. and Pruneri, G. (2013) Tailoring Treatment for Ductal Intraepithelial Neoplasia of the Breast According to Ki-67 and Molecular Phenotype. British Journal of Cancer, 108, 1593-1601. https://doi.org/10.1038/bjc.2013.147
|
[41]
|
Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.J. and Members, P. (2011) Strategies for Subtypes—Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22, 1736-1747. https://doi.org/10.1093/annonc/mdr304
|
[42]
|
Lari, S.A. and Kuerer, H.M. (2011) Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. Journal of Cancer, 2, 232-261. https://doi.org/10.7150/jca.2.232
|
[43]
|
Albonico, G., Querzoli, P., Ferretti, S., Rinaldi, R. and Nenci, I. (1998) Biological Profile of In Situ Breast Cancer Investigated by Immunohistochemical Technique. Cancer Detection and Prevention, 22, 313-318. https://doi.org/10.1046/j.1525-1500.1998.CDOA41.x
|
[44]
|
Ringberg, A., Anagnostaki, L. anderson, H., Idvall, I., Fernö, M. and Group, S.S.B.C. (2001) Cell Biological Factors in Ductal Carcinoma In Situ (DCIS) of the Breast-Relationship to Ipsilateral Local Recurrence and Histopathological Characteristics. European Journal of Cancer, 37, 1514-1522. https://doi.org/10.1016/S0959-8049(01)00165-4
|
[45]
|
Kuerer, H.M., Buzdar, A.U., Mittendorf, E.A., Esteva, F.J., Lucci, A., Vence, L.M., Radvanyi, L., Meric-Bernstam, F., Hunt, K.K. and Symmans, W.F. (2011) Biologic and Immunologic Effects of Preoperative Trastuzumab for Ductal Carcinoma In Situ of the Breast. Cancer, 117, 39-47. https://doi.org/10.1002/cncr.25399
|
[46]
|
Barnes, N.L., Khavari, S., Boland, G.P., Cramer, A., Knox, W.F. and Bundred, N.J. (2005) Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In Situ of the Breast. Clinical Cancer Research, 11, 2163-2168. https://doi.org/10.1158/1078-0432.CCR-04-1633
|
[47]
|
Wärnberg, F., Nordgren, H., Bergkvist, L. and Holmberg, L. (2001) Tumour Markers in Breast Carcinoma Correlate with Grade Rather than with Invasiveness. British Journal of Cancer, 85, 869-874. https://doi.org/10.1054/bjoc.2001.1995
|
[48]
|
Latta, E.K., Tjan, S., Parkes, R.K. and O’Malley, F.P. (2002) The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the Breast. Modern Pathology, 15, 1318-1325. https://doi.org/10.1097/01.MP.0000038462.62634.B1
|
[49]
|
Liao, N., Zhang, G.C., Liu, Y.H., Li, X.R., Yao, M., Xu, F.P., Li, L. and Wu, Y.L. (2011) HER2-Positive Status Is an Independent Predictor for Coexisting Invasion of Ductal Carcinoma In Situ of the Breast Presenting Extensive DCIS Component. Pathology, Research and Practice, 207, 1-7. https://doi.org/10.1016/j.prp.2010.08.005
|
[50]
|
Claus, E.B., Chu, P., Howe, C.L., Davison, T.L., Stern, D.F., Carter, D. and DiGiovanna, M.P. (2001) Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/Neu and Hormone Receptors. Experimental and Molecular Pathology, 70, 303-316. https://doi.org/10.1006/exmp.2001.2366
|
[51]
|
DiGiovanna, M.P., Chu, P., Davison, T.L., Howe, C.L., Carter, D., Claus, E.B. and Stern, D.F. (2002) Active Signaling by HER-2/Neu in a Subpopulation of HER-2/Neu-Overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates. Cancer Research, 62, 6667-6673.
|
[52]
|
Lebeau, A., Unholzer, A., Amann, G., Kronawitter, M., Bauerfeind, I., Sendelhofert, A., Iff, A. and Löhrs, U. (2003) EGFR, HER-2/neu, cyclin D1, p21 and p53 in Correlation to Cell Proliferation and Steroid Hormone Receptor Status in Ductal Carcinoma In Situ of the Breast. Breast Cancer Research and Treatment, 79, 187-198. https://doi.org/10.1023/A:1023958324448
|
[53]
|
Miligy, I.M., Toss, M.S., Gorringe, K.L., Lee, A.H.S., Ellis, I.O., Green, A.R. and Rakha, E.A. (2019) The Clinical and Biological Significance of HER2 Over-Expression in Breast Ductal Carcinoma in Situ: A Large Study from a Single Institution. British Journal of Cancer, 120, 1075-1082. https://doi.org/10.1038/s41416-019-0436-3
|
[54]
|
Borgquist, S., Zhou, W., Jirström, K., Amini, R.M., Sollie, T., Sørlie, T., Blomqvist, C., Butt, S. and Wärnberg, F. (2015) The Prognostic Role of HER2 Expression in Ductal Breast Carcinoma In Situ (DCIS); a Population-Based Cohort Study. BMC Cancer, 15, 468. https://doi.org/10.1186/s12885-015-1479-3
|
[55]
|
Solin, L.J., Gray, R., Baehner, F.L., Butler, S.M., Hughes, L.L., Yoshizawa, C., Cherbavaz, D.B., Shak, S., Page, D.L., Sledge, G.W., Davidson, N.E., Ingle, J.N., Perez, E.A., Wood, W.C., Sparano, J.A. and Badve, S. (2013) A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 105, 701-710. https://doi.org/10.1093/jnci/djt067
|
[56]
|
Allred, D.C., Clark, G.M., Tandon, A.K., Molina, R., Tormey, D.C., Osborne, C.K., Gilchrist, K.W., Mansour, E.G., Abeloff, M. and Eudey, L. (1992) HER-2/neu in Node-Negative Breast Cancer: Prognostic Significance of Overexpression Influenced by the Presence of In Situ Carcinoma. Journal of Clinical Oncology, 10, 599-605. https://doi.org/10.1200/JCO.1992.10.4.599
|
[57]
|
Bartkova, J., Barnes, D.M., Millis, R.R. and Gullick, W.J. (1990) Immunohistochemical Demonstration of c-erbB-2 Protein in Mammary Ductal Carcinoma in Situ. Human Pathology, 21, 1164-1167. https://doi.org/10.1016/0046-8177(90)90154-W
|